Literature DB >> 14308403

[ON THE ACTION MECHANISM OF PHENYLPROPYL-DIPHENYLPROPYLAMINE (SEGONTIN) IN MAN].

H J KUSCHKE, H IDRISS, F ECKMANN.   

Abstract

Entities:  

Keywords:  CATECHOLAMINES; HYPERTENSION; PRENYLAMINE

Mesh:

Substances:

Year:  1965        PMID: 14308403     DOI: 10.1007/bf01879186

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


× No keyword cloud information.
  21 in total

1.  The fluorimetric estimation of catecholamines.

Authors:  H WEIL-MALHERBE
Journal:  Methods Med Res       Date:  1961

2.  Prenylamine ("Segontin") in angina of effort.

Authors:  D E ANDERSON
Journal:  Med J Aust       Date:  1963-02-02       Impact factor: 7.738

3.  ANALYSIS OF THE MG++-ATP DEPENDENT STORAGE MECHANISM IN THE AMINE GRANULES OF THE ADRENAL MEDULLA.

Authors:  A CARLSSON; N A HILLARP; B WALDECK
Journal:  Acta Physiol Scand Suppl       Date:  1963

4.  EFFECTS OF SMALL ORAL DOSES OF RESERPINE ON VASCULAR RESPONSES TO TYRAMINE AND NOREPINEPHRINE IN MAN.

Authors:  F M ABBOUD; J W ECKSTEIN
Journal:  Circulation       Date:  1964-02       Impact factor: 29.690

5.  [Hemodynamic effects after segontin injection].

Authors:  D MICHEL
Journal:  Bull Off Chambre Synd Med Seine       Date:  1960-08-12

6.  [A new coronary vasodilator. Experimental and clinical studies].

Authors:  C BOEHM; M SCHLEPPER; E WITZLEB
Journal:  Dtsch Med Wochenschr       Date:  1960-08-05       Impact factor: 0.628

7.  [A double-blind experiment with the coronary therapeutic agent segontin].

Authors:  H OVERKAMP
Journal:  Med Klin       Date:  1960-08

8.  [Clinical experiences with segontin].

Authors:  M RATSCHOW; W SCHOOP
Journal:  Med Klin       Date:  1960-08-12

9.  [Excretion of noradrenalin and adrenalin under massive reserpine therapy].

Authors:  H J KUSCHKE; H VON DITFURTH
Journal:  Klin Wochenschr       Date:  1958-08-15

10.  THE PRESSOR EFFECT OF TYRAMINE IN MAN AND ITS MODIFICATION BY RESERPINE PRETREATMENT.

Authors:  W A Mahon; M L Mashford
Journal:  J Clin Invest       Date:  1963-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.